Literature DB >> 28439342

Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.

April W Armstrong1, Ron Vender2, Leon Kircik3.   

Abstract

Entities:  

Year:  2016        PMID： 28439342      PMCID： PMC5395240     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN： 1941-2789


× No keyword cloud information.
  24 in total

1.  Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study.

Authors:  T J Love; J E Gudjonsson; H Valdimarsson; B Gudbjornsson
Journal:  Scand J Rheumatol       Date:  2010-08       Impact factor: 3.641

2.  Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice.

Authors:  Adam A Pettey; Rajesh Balkrishnan; Stephen R Rapp; Alan B Fleischer; Steven R Feldman
Journal:  J Am Acad Dermatol       Date:  2003-08       Impact factor: 11.527

3.  Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation.

Authors:  C Stanley Chan; Abby S Van Voorhees; Mark G Lebwohl; Neil J Korman; Melodie Young; Bruce F Bebo; Robert E Kalb; Sylvia Hsu
Journal:  J Am Acad Dermatol       Date:  2009-04-17       Impact factor: 11.527

4.  Palmoplantar lesions in psoriasis: a study of 3065 patients.

Authors:  Bhushan Kumar; Abir Saraswat; Inderjeet Kaur
Journal:  Acta Derm Venereol       Date:  2002       Impact factor: 4.437

5.  Secukinumab in plaque psoriasis--results of two phase 3 trials.

Authors:  Richard G Langley; Boni E Elewski; Mark Lebwohl; Kristian Reich; Christopher E M Griffiths; Kim Papp; Lluís Puig; Hidemi Nakagawa; Lynda Spelman; Bárður Sigurgeirsson; Enrique Rivas; Tsen-Fang Tsai; Norman Wasel; Stephen Tyring; Thomas Salko; Isabelle Hampele; Marianne Notter; Alexander Karpov; Silvia Helou; Charis Papavassilis
Journal:  N Engl J Med       Date:  2014-07-09       Impact factor: 91.245

6.  Nail disease in psoriatic arthritis: distal phalangeal bone edema detected by magnetic resonance imaging predicts development of onycholysis and hyperkeratosis.

Authors:  Nicola Dalbeth; Karen Pui; Maria Lobo; Anthony Doyle; Peter B Jones; William J Taylor; Fiona M McQueen
Journal:  J Rheumatol       Date:  2012-02-15       Impact factor: 4.666

7.  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).

Authors:  Phoebe Rich; Melinda Gooderham; Hervé Bachelez; Joana Goncalves; Robert M Day; Rongdean Chen; Jeffrey Crowley
Journal:  J Am Acad Dermatol       Date:  2016-01       Impact factor: 11.527

8.  Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

Authors:  K A Papp; C E M Griffiths; K Gordon; M Lebwohl; P O Szapary; Y Wasfi; D Chan; M-C Hsu; V Ho; P D Ghislain; B Strober; K Reich
Journal:  Br J Dermatol       Date:  2013-04       Impact factor: 9.302

9.  Recommendations for a patient-centered approach to the assessment and treatment of scalp psoriasis: a consensus statement from the Asia Scalp Psoriasis Study Group.

Authors:  Maria Lorna F Frez; Pravit Asawanonda; Chalukya Gunasekara; Chuankeng Koh; Steven Loo; Hazel H Oon; Vu Hong Thai; Tsen-Fang Tsai; Sang Woong Youn
Journal:  J Dermatolog Treat       Date:  2013-01-20       Impact factor: 3.359

Review 10.  Interleukin-17 as a drug target in human disease.

Authors:  Stefan Ivanov; Anders Lindén
Journal:  Trends Pharmacol Sci       Date:  2009-01-21       Impact factor: 14.819
View more
  9 in total

Review 1.  Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.

Authors:  Alan Menter; Tina Bhutani; Benjamin Ehst; Boni Elewski; Abby Jacobson
Journal:  Dermatol Ther (Heidelb)       Date:  2022-06-07

Review 2.  IgA vasculitis during secukinumab therapy.

Authors:  Dijana Perkovic; Petra Simac; Josip Katic
Journal:  Clin Rheumatol       Date:  2020-08-29       Impact factor: 2.980

3.  Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.

Authors:  Marina Talamonti; Giovanna Malara; Ylenia Natalini; Federico Bardazzi; Andrea Conti; Andrea Chiricozzi; Cristina Mugheddu; Paolo Gisondi; Stefano Piaserico; Gianluca Pagnanelli; Paolo Amerio; Concetta Potenza; Franca Cantoresi; Maria Concetta Fargnoli; Anna Balato; Francesco Loconsole; Annamaria Offidani; Claudio Bonifati; Francesca Prignano; Marta Bartezaghi; Alice Rausa; Elisabetta Aloisi; Roberto Orsenigo; Antonio Costanzo
Journal:  Acta Derm Venereol       Date:  2021-03-31       Impact factor: 3.875

Review 4.  Secukinumab in the treatment of psoriasis: patient selection and perspectives.

Authors:  Eric J Yang; Kristen M Beck; Wilson Liao
Journal:  Psoriasis (Auckl)       Date:  2018-10-17

5.  Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.

Authors:  A Deodhar; P J Mease; I B McInnes; X Baraliakos; K Reich; A Blauvelt; C Leonardi; B Porter; A Das Gupta; A Widmer; L Pricop; T Fox
Journal:  Arthritis Res Ther       Date:  2019-05-02       Impact factor: 5.156

6.  Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.

Authors:  B E Elewski; C S Baker; J J Crowley; Y Poulin; M M Okun; B Calimlim; Z Geng; O Reyes Servin; P A Rich
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-09-04       Impact factor: 6.166

7.  Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations.

Authors:  Seungkeol Yang; Bo Ri Kim; Minsu Kim; Sang Woong Youn
Journal:  Ann Dermatol       Date:  2021-03-08       Impact factor: 1.444

Review 8.  Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities.

Authors:  Alan Menter; Gerald G Krueger; So Yeon Paek; Dario Kivelevitch; Iannis E Adamopoulos; Richard G Langley
Journal:  Dermatol Ther (Heidelb)       Date:  2021-01-29

9.  Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records.

Authors:  April W Armstrong; Dhaval Patil; Eugenia Levi; Catherine B McGuiness; Xin Wang; Yi Wang; Chi-Chang Chen; Elizabeth Nguyen; Paul S Yamauchi
Journal:  Dermatol Ther (Heidelb)       Date:  2021-08-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.